Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of "Failed" R&D Efforts.

Xie, Richard Z; Towse, Adrian; Garrison, Louis P

Xie, Richard Z; Towse, Adrian; Garrison, Louis P.

Afiliación

Xie RZ; The Innovation and Value Initiative, Alexandria, VA, USA.
Towse A; Office of Health Economics, London, United Kingdom.
Garrison LP; The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA.

Int J Technol Assess Health Care ; 38(1): e31, 2022 Mar 17.

Article en En | MEDLINE | ID: mdl-35297363

Asunto(s)

COVID-19; Industria Farmacéutica; Humanos; Preparaciones Farmacéuticas; Investigación

Palabras clave

Drug development; Health economics; Health policy; Reimbursement; Social welfare

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Industria Farmacéutica / COVID-19 Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Industria Farmacéutica / COVID-19 Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article